Treatment of panic disorder: recent developments and current status

References

• Wittchen H-U, Nocon A, Beesdo K et al. Agoraphobia and panic: prospective-longitudinal relations suggest a rethinking of diagnostic concepts. Psychother. Psychosom.77, 147–157 (2008).
   PubMed Web of Science ®Google Scholar
• Faravelli C, Cosci F, Rotella F, Faravelli L, Dell’Osso MC. Agoraphobia between panic and phobias: clinical epidemiology from the Sesto Fiorentino Study. Compr. Psychiatry49, 283–287 (2008).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry63, 415–424 (2006).
   PubMed Web of Science ®Google Scholar
• Katon W. Panic disorder: relationship to high medical utilization, unexplained physical symptoms, and medical costs. J. Clin. Psychiatry57(Suppl. 10), 11–22 (1996).
   PubMed Web of Science ®Google Scholar
• Tyrer P, Seivewright H Johnson T. The Nottingham study of neurotic disorder: predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder. Psychol. Med.34, 1385–1394 (2004).
   PubMed Web of Science ®Google Scholar
• Sareen J, Cox BJ, Afifi TO et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch. Gen. Psychiatry62, 1249–1257 (2005).
   PubMed Web of Science ®Google Scholar
• Smoller JW, Pollack MH, Wassertheil-Smoller S et al. Panic attacks and risk of incident cardiovascular vents among postmenopausal women in the Women’s Health Initiative observational Study. Arch. Gen. Psychiatry64, 1153–1160 (2007).
   PubMed Web of Science ®Google Scholar
• Stein MB, Sherbourne CD, Craske MG et al. Quality of care for primary care patients with anxiety disorders. Am. J. Psychiatry161, 2230–2237 (2004).
   PubMed Web of Science ®Google Scholar
• Nadiga DN, Hensley PL, Uhlenhuth EH. Review of the long-term effectiveness of cognitive behavioral therapy compared to medications in panic disorder. Depress. Anxiety17, 58–64 (2003).
   PubMed Web of Science ®Google Scholar
• Fava GA, Rafanelli C, Grandi S et al. Long-term outcome of panic disorder with agoraphobia treated by exposure. Psychol. Med.31, 891–898 (2001).
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Pollack MH, Clary CM, Mardekian J, Wolkow R. Panic disorder and response to sertraline: the effect of previous treatment with benzodiazepines. J. Clin. Psychopharmacol.21, 104–107 (2001).
   PubMed Web of Science ®Google Scholar
• Mavissakalian MR, Perel JM. Duration of imipramine therapy and relapse in panic disorder with agoraphobia. J. Clin. Psychopharmacol.22, 294–299 (2002).
   PubMed Web of Science ®Google Scholar
• Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J. Affect. Disord.88, 27–45 (2005).
   PubMed Web of Science ®Google Scholar
• Dusseldorp E, Spinhoven P, Bakker A, van Dyck R, van Balkom AJLM. Which panic disorder patients benefit from which treatment: cognitive therapy or antidepressants? Psychother. Psychosom.76, 154–161 (2007).
   PubMed Web of Science ®Google Scholar
• Shear MK, Brown TA, Barlow DH et al. Multicenter collaborative Panic Disorder Severity Scale. Am. J. Psychiatry154, 1571–1575 (1997).
   PubMed Web of Science ®Google Scholar
• Bandelow B. Assessing the efficacy of treatment for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int. Clin. Psychopharmacol.10, 73–81 (1995).
   PubMed Web of Science ®Google Scholar
• öst L-G, Thulin U, Ramnerö J. Cognitive behavior therapy vs. exposure in vivo in the treatment of panic disorder with agoraphobia. Behav. Res. Ther.42, 1105–1127 (2004).
   PubMed Web of Science ®Google Scholar
• Salkovskis PM, Hackmann A, Wells A, Gelder MG, Clark DM. Belief disconfirmation versus habituation approaches to situational exposure in panic disorder with agoraphobia: a pilot study. Behav. Res. Ther.44, 877–885 (2006).
   Google Scholar
• Norton PJ, Price EC. A meta-analytic review of adult cognitive–behavioral treatment outcome across the anxiety disorders. J. Nerv. Ment. Dis.195, 521–531 (2007).
   PubMed Web of Science ®Google Scholar
• Hofmann SG, Smits JAJ. Cognitive–behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J. Clin. Psychiatry69, 621–632 (2008).
   PubMed Web of Science ®Google Scholar
• Smits JAJ, Powers MB, Cho Y, Telch MJ. Mechanism of change in cognitive–behavioral treatment of panic disorder: evidence for the fear of fear mediational hypothesis. J. Consult. Clin. Psychol.72, 646–652 (2004).
   PubMed Web of Science ®Google Scholar
• Hofmann SG, Meuret AE, Rosenfield D et al. Preliminary evidence for cognitive mediation during cognitive–behavioral therapy of panic disorder. J. Consult. Clin. Psychol.75, 374–379 (2007).
   PubMed Web of Science ®Google Scholar
• Bouchard S, Gauthier J, Nouwen A et al. Temporal relationship between dysfunctional beliefs, self-efficacy and panic apprehension in the treatment of panic disorder with agoraphobia. J. Behav. Ther. Exp. Psychiatry38, 275–292 (2007).
   PubMed Web of Science ®Google Scholar
• Hofmann SG. Cognitive processes during fear acquisition and extinction in animals and humans: implications for exposure therapy of anxiety disorders. Clin. Psychol. Rev.28, 200–211 (2008).
   Google Scholar
• Longmore RJ, Worrell M. Do we need to challenge thoughts in cognitive behavior therapy? Clin. Psychol. Rev.27, 173–187 (2007).
   PubMed Web of Science ®Google Scholar
• Johansson P, Høglend P. Identifying mechanisms of change in psychotherapy: mediators of treatment outcome. Clin. Psychol. Psychother.14, 1–9 (2007).
   Web of Science ®Google Scholar
• Addis ME, Hatgis C, Krasnow AD, Jacob K, Bourne L, Mansfield A. Effectiveness of cognitive–behavioral treatment for panic disorder versus treatment as usual in a managed care setting. J. Consult. Clin. Psychol.72, 625–635 (2004).
   PubMed Web of Science ®Google Scholar
• Addis ME, Hatgis C, Cardemil E, Jacob K, Krasnow AD, Mansfield A. Effectiveness of cognitive–behavioral treatment for panic disorder versus treatment as usual in a managed care setting: 2-year follow-up. J. Consult. Clin. Psychol.74, 377–385 (2006).
   PubMed Web of Science ®Google Scholar
• Roy-Byrne PP, Katon W, Cowley DS, Russo J. A randomized effectiveness trial of collaborative care for patients with panic disorder in primary care. Arch. Gen. Psychiatry58, 869–876 (2001).
   PubMed Web of Science ®Google Scholar
• Roy-Byrne PP, Craske MG, Stein MB et al. A randomized effectiveness trial of cognitive–behavioral therapy and medication for primary care panic disorder. Arch. Gen. Psychiatry62, 290–298 (2005).
   PubMed Web of Science ®Google Scholar
• Rollman BL, Belnap BH, Mazumdar S et al. A randomized trial to improve the quality of treatment for panic and generalized anxiety disorders in primary care. Arch. Gen. Psychiatry62, 1332–1341 (2005).
   PubMed Web of Science ®Google Scholar
• van Apeldoorn FJ, van Hout WJPJ, Mersch PPA et al. Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia. Acta Psychiatr. Scand.117, 260–270 (2008).
   PubMed Web of Science ®Google Scholar
• Dow MGT, Kenardy JA, Johnston DW, Newman MG, Taylor CB, Thomson A. Prognostic indices with brief and standard CBT for panic disorder: II. Moderators of outcome. Psychol. Med.37, 1503–1509 (2007).
   PubMed Web of Science ®Google Scholar
• Deacon B, Abramowitz J. A pilot study of two-day cognitive–behavioral therapy for panic disorder. Behav. Res. Ther.44, 807–817 (2006).
   PubMed Web of Science ®Google Scholar
• Lamplugh C, Berle D, Milicevic D, Starcevic V. A pilot study of cognitive–behaviour therapy for panic disorder augmented by panic surfing. Clin. Psychol. Psychother. (in press).
   Google Scholar
• Morissette SB, Spiegel DA, Heinrichs N. Sensation-focused intensive treatment for panic disorder with moderate to severe agoraphobia. Cogn. Behav. Practice12, 17–29 (2005).
   Web of Science ®Google Scholar
• Bitran S, Morissette SB, Spiegel DA, Barlow DH. A pilot study of sensation-focused intensive treatment for panic disorder with moderate to severe agoraphobia: preliminary outcome and benchmarking data. Behav. Modif.32, 196–214 (2008).
   PubMed Web of Science ®Google Scholar
• Sharp DM, Power KG, Swanson V. A comparison of the efficacy and acceptability of group versus individual cognitive behaviour therapy in the treatment of panic disorder and agoraphobia in primary care. Clin. Psychol. Psychother.11, 73–82 (2004).
   Web of Science ®Google Scholar
• Marks IM, Kenwright M, McDonough M, Whittaker M, Mataix-Cols D. Saving clinicians’ time by delegating routine aspects of therapy to a computer: a randomized controlled trial in phobia/panic disorder. Psychol. Med.34, 9–18 (2004).
   PubMed Web of Science ®Google Scholar
• Carlbring P, Bohman S, Brunt S et al. Remote treatment of panic disorder: a randomized trial of internet-based cognitive behavior therapy supplemented with telephone calls. Am. J. Psychiatry163, 2119–2125 (2006).
   PubMed Web of Science ®Google Scholar
• Klein B, Richards JC, Austin DW. Efficacy of internet therapy for panic disorder. J. Behav. Ther. Exp. Psychiatry37, 213–238 (2006).
   PubMed Web of Science ®Google Scholar
• Villa Martin H, Botella C, Garcia-Palacios A, Osma J. Virtual reality exposure in the treatment of panic disorder with agoraphobia: a case study. Cogn. Behav. Practice14, 58–69 (2007).
   Web of Science ®Google Scholar
• Botella C, Garcia-Palacios A, Villa H et al. Virtual reality exposure in the treatment of panic disorder and agoraphobia: a controlled study. Clin. Psychol. Psychother.14, 164–175 (2007).
   Web of Science ®Google Scholar
• Cowley DS, Ha EH, Roy-Byrne PP. Determinants of pharmacologic treatment failure in panic disorder. J. Clin. Psychiatry58, 555–561 (1997).
   PubMed Web of Science ®Google Scholar
• Schweizer E, Rickels K, Weiss S, Zavodnick S. Maintenance drug treatment of panic disorder: I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch. Gen. Psychiatry50, 51–60 (1993).
   PubMed Web of Science ®Google Scholar
• Bakker A, van Balkom AJLM, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr. Scand.106, 163–167 (2002).
   PubMed Web of Science ®Google Scholar
• Otto MW, Tuby KS, Gould RA, McLean RS, Pollack MH. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am. J. Psychiatry158, 1989–1992 (2001).
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am. J. Psychiatry155, 36–42 (1998).
   PubMed Web of Science ®Google Scholar
• Londborg PD, Wolkow R, Smith WT. Sertraline in the treatment of panic disorder: a multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br. J. Psychiatry173, 54–60 (1998).
   PubMed Web of Science ®Google Scholar
• Bandelow B, Behnke K, Lenoir S et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J. Clin. Psychiatry65, 405–413 (2004).
   PubMed Web of Science ®Google Scholar
• Mavissakalian M, Perel JM. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. Am. J. Psychiatry152, 673–682 (1995).
   PubMed Web of Science ®Google Scholar
• Rosenbaum JF, Moroz G, Bowden CL. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose–response study of efficacy, safety, and discontinuance. J. Clin. Psychopharmacol.17, 390–400 (1997).
   PubMed Web of Science ®Google Scholar
• Nagy LM, Krystal JH, Woods SW, Charney DS. Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic follow-up study. Arch. Gen. Psychiatry46, 993–999 (1989).
   PubMed Web of Science ®Google Scholar
• Pollack MH, Otto MW, Tesar GE, Cohen LS, Meltzer-Brody S, Rosenbaum JF. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J. Clin. Psychopharmacol.13, 257–263 (1993).
   PubMed Web of Science ®Google Scholar
• Worthington JJ, Pollack MH, Otto MW, McLean RYS, Moroz G, Rosenbaum JF. Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder. Psychopharmacol. Bull.34, 199–205 (1998).
   PubMedGoogle Scholar
• Salzman C, Miyawaki EK, le Bars P, Kerrihard TN. Neurobiologic basis of anxiety and its treatment. Harv. Rev. Psychiatry1, 197–206 (1993).
   PubMed Web of Science ®Google Scholar
• Pollack MH, Lepola U, Koponen H et al. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress. Anxiety24, 1–14 (2007).
   PubMed Web of Science ®Google Scholar
• Ferguson JM, Khan A, Mangano R, Entsuah R, Tzanis E. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J. Clin. Psychiatry68, 58–68 (2007).
   PubMed Web of Science ®Google Scholar
• Woods SW, Nagy LM, Koleszar AS, Krystal JH, Heninger GR, Charney DS. Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. J. Clin. Psychopharmacol.12, 32–38 (1992).
   PubMed Web of Science ®Google Scholar
• Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney S. Early coadministration of clonazepam with sertraline for panic disorder. Arch. Gen. Psychiatry58, 681–686 (2001).
   PubMed Web of Science ®Google Scholar
• Pollack MH, Simon NM, Worthington JJ et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J. Psychopharmacol.17, 276–282 (2003).
   PubMed Web of Science ®Google Scholar
• Fava GA, Bernardi M, Tomba E, Rafanelli C. Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int. J. Neuropsychopharmacol.10, 835–838 (2007).
   PubMed Web of Science ®Google Scholar
• Mavissakalian M, Perel JM. Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. Am. J. Psychiatry149, 1053–1057 (1992).
   PubMed Web of Science ®Google Scholar
• Choy Y, Peselow ED, Case BG et al. Three-year medication prophylaxis in panic disorder: to continue or discontinue? A naturalistic study. Compr. Psychiatry48, 419–425 (2007 ).
   PubMed Web of Science ®Google Scholar
• Blaya C, Seganfredo AC, Dornelles M et al. The efficacy of milnacipran in panic disorder: an open trial. Int. Clin. Psychopharmacol.22, 153–158 (2007).
   PubMed Web of Science ®Google Scholar
• Papp LA. Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. J. Clin. Psychiatry67, 1573–1576 (2006).
   PubMed Web of Science ®Google Scholar
• Pande AC, Pollack MH, Crockatt J et al. Placebo-controlled study of gabapentin treatment of panic disorder. J. Clin. Psychopharmacol.20, 467–471 (2000).
   PubMed Web of Science ®Google Scholar
• Hollifield M, Thompson PM, Ruiz JE, Uhlenhuth EH. Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress. Anxiety21, 33–40 (2005).
   PubMed Web of Science ®Google Scholar
• Sepede G, De Berardis D, Gambi F et al. Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J. Clin. Psychopharmacol.26, 45–49 (2006).
   PubMed Web of Science ®Google Scholar
• Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br. J. Psychiatry188, 305–312 (2006).
   PubMed Web of Science ®Google Scholar
• Watanabe N, Churchill R, Furukawa TA. Combination of psychotherapy and benzodiazepines versus either therapy alone for panic disorder: a systematic review. BMC Psychiatry7, 18 (2007).
   PubMed Web of Science ®Google Scholar
• McHugh RK, Otto MW, Barlow DH, Gorman JM, Shear MK, Woods SW. Cost-efficacy of individual and combined treatments for panic disorder. J. Clin. Psychiatry68, 1038–1044 (2007).
   PubMed Web of Science ®Google Scholar
• Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive–behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA283, 2529–2536 (2000).
   PubMed Web of Science ®Google Scholar
• Craske MG, Golinelli D, Stein MB, Roy-Byrne P, Bystritsky A, Sherbourne C. Does the addition of cognitive–behavioral therapy improve panic disorder treatment outcome relative to medication alone in the primary-care setting? Psychol. Med.35, 1645–1654 (2005).
   PubMed Web of Science ®Google Scholar
• Marks IM, Swinson RP, Basoglu M et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia: a controlled study in London and Toronto. Br. J. Psychiatry162, 776–787 (1993).
   PubMed Web of Science ®Google Scholar
• Wardle J, Hayward P, Higgitt A, Stabl M, Blizard R, Gray J. Effects of concurrent diazepam treatment on the outcome of exposure therapy in agoraphobia. Behav. Res. Ther.32, 203–215 (1994).
   PubMed Web of Science ®Google Scholar
• Basoglu M, Marks IM, Kilic C, Brewin CR, Swinson RP. Alprazolam and exposure for panic disorder with agoraphobia: attribution of improvement to medication predicts subsequent relapse. Br. J. Psychiatry164, 652–659 (1994).
   PubMed Web of Science ®Google Scholar
• Starcevic V, Linden M, Uhlenhuth EH, Kolar D, Latas M. Treatment of panic disorder with agoraphobia in an anxiety disorders clinic: factors influencing psychiatrists’ treatment choices. Psychiatry Res.125, 41–52 (2004).
   PubMed Web of Science ®Google Scholar
• Wiborg IM, Dahl AA. Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Arch. Gen. Psychiatry53, 689–694 (1996).
   PubMed Web of Science ®Google Scholar
• Arch JJ, Craske MG. Implications of naturalistic use of pharmacotherapy in CBT treatment for panic disorder. Behav. Res. Ther.45, 1435–1447 (2007).
   PubMed Web of Science ®Google Scholar
• Mavissakalian MR, Guo S. Early detection of relapse in panic disorder. Acta Psychiatr. Scand.110, 393–399 (2004).
   PubMed Web of Science ®Google Scholar
• Ressler KJ, Rothbaum BO, Tannenbaum L et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch. Gen. Psychiatry61, 1136–1144 (2004).
   PubMed Web of Science ®Google Scholar
• Hofmann SG, Meuret AE, Smits JAJ et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch. Gen. Psychiatry63, 298–304 (2006).
   PubMed Web of Science ®Google Scholar
• Guastella AJ, Richardson R, Lovibond PF et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol. Psychiatry63, 544–549 (2008).
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Buhlmann U, Tolin DF et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am. J. Psychiatry165, 335–341 (2008).
   PubMed Web of Science ®Google Scholar
• Tolin DF, Pearlson GD, Krystal JH et al. A controlled trial of D-cycloserine with brief CBT for panic disorder. Presented at: The 40th Annual Convention of the Association for Behavioral and Cognitive Therapies, Chicago (2006).
   Google Scholar
• Richardson R, Ledgerwood L, Cranney J. Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. Learn. Mem.11, 510–516 (2004).
   PubMed Web of Science ®Google Scholar
• Guastella AJ, Dadds MR, Lovibond PF, Mitchell P, Richardson R. A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. J. Psychiatr. Res.41, 466–471 (2007).
   PubMed Web of Science ®Google Scholar
• Storch EA, Merlo LJ, Bengtson M et al.D-cycloserine does not enhance exposure-response prevention therapy in obsessive–compulsive disorder. Int. Clin. Psychopharmacol.22, 230–237 (2007).
   PubMed Web of Science ®Google Scholar
• Milrod BL, Busch FN, Cooper AM, Shapiro T. Manual of Panic-Focused Psychodynamic Psychotherapy. American Psychiatric Press, Washington, DC, USA (1997).
   Google Scholar
• Milrod B, Busch F, Leon AC et al. Open trial of psychodynamic psychotherapy for panic disorder: a pilot study. Am. J. Psychiatry157, 1878–1880 (2000).
   PubMed Web of Science ®Google Scholar
• Milrod B, Busch F, Leon AC et al. A pilot open trial of brief psychodynamic psychotherapy for panic disorder. J. Psychother. Pract. Res.10, 239–245 (2001).
   PubMed Web of Science ®Google Scholar
• Milrod B, Leon AC, Busch F et al. A randomized controlled clinical trial of psychoanalytic psychotherapy for panic disorder. Am. J. Psychiatry164, 265–272 (2007).
   PubMed Web of Science ®Google Scholar
• Milrod BL, Leon AC, Barber JP, Markowitz JC, Graf E. Do comorbid personality disorders moderate panic-focused psychotherapy? An exploratory examination of the American Psychiatric Association Practice Guidelines. J. Clin. Psychiatry68, 885–891 (2007).
   PubMed Web of Science ®Google Scholar
• Lipsitz JD, Gur M, Miller NL, Forand N, Vermes D, Fyer AJ. An open pilot study of interpersonal psychotherapy for panic disorder (IPT-PD). J. Nerv. Ment. Dis.194, 440–445 (2006).
   PubMed Web of Science ®Google Scholar
• Ströhle A, Feller C, Onken M, Godemann F, Heinz A, Dimeo F. The acute antipanic activity of aerobic exercise. Am. J. Psychiatry162, 2376–2378 (2005).
   PubMed Web of Science ®Google Scholar
• Broocks A, Bandelow B, Pekrun G et al. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am. J. Psychiatry155, 603–609 (1998).
   PubMed Web of Science ®Google Scholar
• Smits JAJ, Powers MB, Berry AC, Otto MW. Translating empirically supported strategies into accessible interventions: the potential utility of exercise for the treatment of panic disorder. Cogn. Behav. Practice14, 364–374 (2007).
   Web of Science ®Google Scholar